Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 15%
Hold 62%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis is a promising biopharmaceutical firm with a strong presence in the cancer treatment market thanks to its successful drug, Cabometyx. The company continues to see growth in script sales and has a durable, cash-generative franchise. However, there are inherent risks in drug development and the looming 2031 LOE for Cabometyx raises the stakes for their next leg, potentially leading to a need for additional financing.

Bears say

Exelixis is a biotechnology company that has seen a significant decrease in net income due to a $51.7 million impairment of long-lived assets. While the company has a promising pipeline, particularly with the development of zanzalintinib and an early-stage ADC platform, their flagship product Cabometyx will face LOEs in 2031 and the company has only a Hold rating at this time.

Exelixis (EXEL) has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 15% recommend Buy, 62% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 13 analysts, Exelixis (EXEL) has a Buy consensus rating as of Aug 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.